PASADENA, Calif. Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) unveiled promising new data from their Phase 3 PALISADE study of plozasiran, an investigational treatment for familial chylomicronemia syndrome (FCS), during the European Society of Cardiology (ESC) Congress 2024. FCS is a severe and rare genetic disorder with no currently approved treatments in the United States.’
The PALISADE study successfully achieved its primary endpoint and all key secondary endpoints, showing statistically significant reductions in triglycerides (TGs) and apolipoprotein B (ApoB). These encouraging results bolster the potential of plozasiran as a groundbreaking therapy for FCS, aiming to address the unmet medical needs of patients who suffer from this debilitating condition.
Dr. Christopher Anzalone, President and CEO of Arrowhead Pharmaceuticals, commented on the findings: The positive results from the PALISADE study mark a significant milestone in our mission to develop innovative therapies for patients with rare genetic diseases. We are optimistic about the future of plozasiran and its potential to transform the lives of those living with FCS.
Despite these scientific advancements, Arrowhead Pharmaceuticals reported a cumulative net loss of $547 million for the 12 months ending in the third quarter of 2024. This resulted in a negative return on assets (ROA) of -71.59%. Within the Healthcare sector, 424 other companies recorded a higher ROA during the same timeframe.
However, Arrowhead’s overall ROA ranking has shown progress, advancing to 2917 in the June 30, 2024 quarter, up from the 3339 ranking in the second quarter of 2024. This improvement reflects the company’s ongoing efforts to strengthen its financial performance while continuing to focus on research and development in the biopharmaceutical space.
As Arrowhead Pharmaceuticals moves forward with the regulatory process for plozasiran, the company remains committed to delivering innovative treatments that can address significant unmet medical needs and improve patient outcomes.
Comments